Xavier Montalban

MD, PhD

Scientist, Li Ka Shing Knowledge Institute

Research Programs

Biography

Dr. Xavier Montalban is an internationally recognized neurologist who is considered a key opinion leader within the field of multiple sclerosis (MS). Dr. Montalban has held diverse leadership positions and is currently a Professor of Medicine and Director of the Neurology Department at the University of Toronto. He also serves as Chair of the Department of Neurology-Neuroimmunology and Director of the Multiple Sclerosis Centre of Catalonia at the Vall d’Hebron University Hospital in Barcelona, Spain. The Multiple Sclerosis Centre of Catalonia, or Cemcat, is accredited as a national flagship service for the MS care process within the context of the Flagship Centres, Units, and Services programme of the Spanish Ministry of Health. Dr. Montalban is a former president of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and recently co-directed the development of the first Multiple Sclerosis Treatment Guidelines for ECTRIMS and the European Academy of Neurology. He has contributed more than 500 publications and several book chapters to the academic arena, served on multiple steering committees of clinical trials related to multiple sclerosis, and is a valued member of the International Panel on Multiple Sclerosis Diagnostic Criteria and Clinical Trials. With more than 25 years of research, Dr. Montalban continues to strive to discover more effective therapies for patients with MS and has brought paradigm shifts to the way we understand and treat MS.

Recent Publications

  1. Pappolla, A, Midaglia, L, Boix Rodríguez, CP, Puig, AA, Lung, M, Camps, IR et al.. Simultaneous CMV and Listeria infection following alemtuzumab treatment for multiple sclerosis. Neurology. 2018; :. doi: 10.1212/WNL.0000000000006801. PubMed PMID:30587519 .
  2. Gasperini, C, Prosperini, L, Tintoré, M, Sormani, MP, Filippi, M, Rio, J et al.. Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge. Neurology. 2018; :. doi: 10.1212/WNL.0000000000006810. PubMed PMID:30587516 .
  3. Costa, C, Eixarch, H, Martínez-Sáez, E, Calvo-Barreiro, L, Calucho, M, Castro, Z et al.. Expression of Bone Morphogenetic Proteins In Multiple Sclerosis Lesions. Am. J. Pathol. 2018; :. doi: 10.1016/j.ajpath.2018.11.007. PubMed PMID:30553833 .
  4. Amezcua, L, Beecham, AH, Delgado, SR, Chinea, A, Burnett, M, Manrique, CP et al.. Native ancestry is associated with optic neuritis and age of onset in hispanics with multiple sclerosis. Ann Clin Transl Neurol. 2018;5 (11):1362-1371. doi: 10.1002/acn3.646. PubMed PMID:30480030 PubMed Central PMC6243381.
  5. Jensen, PEH, Warnke, C, Ingenhoven, K, Piccoli, L, Gasis, M, Hermanrud, C et al.. Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. J. Neuroimmunol. 2019;326 :19-27. doi: 10.1016/j.jneuroim.2018.11.002. PubMed PMID:30447419 .
  6. Fox, EJ, Markowitz, C, Applebee, A, Montalban, X, Wolinsky, JS, Belachew, S et al.. Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial. Mult. Scler. 2018;24 (14):1862-1870. doi: 10.1177/1352458518808189. PubMed PMID:30415593 PubMed Central PMC6282157.
  7. Malhotra, S, Villar, LM, Costa, C, Midaglia, L, Cubedo, M, Medina, S et al.. Circulating EZH2-positive T cells are decreased in multiple sclerosis patients. J Neuroinflammation. 2018;15 (1):296. doi: 10.1186/s12974-018-1336-9. PubMed PMID:30367633 PubMed Central PMC6202809.
  8. Soelberg Sorensen, P, Giovannoni, G, Montalban, X, Thalheim, C, Zaratin, P, Comi, G et al.. The Multiple Sclerosis Care Unit. Mult. Scler. 2018; :1352458518807082. doi: 10.1177/1352458518807082. PubMed PMID:30351211 .
  9. International Multiple Sclerosis Genetics Consortium. Electronic address: chris.cotsapas@yale.edu, International Multiple Sclerosis Genetics Consortium. Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. Cell. 2018;175 (6):1679-1687.e7. doi: 10.1016/j.cell.2018.09.049. PubMed PMID:30343897 PubMed Central PMC6269166.
  10. Saposnik, G, Montalban, X, Selchen, D, Terzaghi, MA, Bakdache, F, Montoya, A et al.. Therapeutic Inertia in Multiple Sclerosis Care: A Study of Canadian Neurologists. Front Neurol. 2018;9 :781. doi: 10.3389/fneur.2018.00781. PubMed PMID:30319523 PubMed Central PMC6165907.
Search PubMed

Affiliations & Other Activities

  • The Waugh Family Chair in Multiple Sclerosis Research, St. Michael’s Hospital
  • Medical Director, the BARLO MS Centre, St. Michael’s Hospital
  • Professor, Department of Medicine, University of Toronto
  • Division Director, Department of Neurology, University of Toronto
  • Director, Centre d’Esclerosi Múltiple de Catalunya (Cemcat)
X